Share on StockTwits

Aegerion Pharmaceuticals (NASDAQ:AEGR)‘s stock had its “buy” rating restated by stock analysts at Deutsche Bank in a report issued on Friday. They currently have a $58.00 price objective on the stock, down from their previous price objective of $70.00. Deutsche Bank’s price target suggests a potential upside of 94.17% from the company’s current price.

AEGR has been the subject of a number of other recent research reports. Analysts at Zacks reiterated a “neutral” rating on shares of Aegerion Pharmaceuticals in a research note on Wednesday, July 16th. They now have a $29.00 price target on the stock. Analysts at Goldman Sachs initiated coverage on shares of Aegerion Pharmaceuticals in a research note on Tuesday, May 27th. They set a “sell” rating and a $27.00 price target on the stock. One investment analyst has rated the stock with a sell rating, four have issued a hold rating and four have assigned a buy rating to the company’s stock. The company presently has a consensus rating of “Hold” and an average price target of $61.75.

Aegerion Pharmaceuticals (NASDAQ:AEGR) traded down 0.20% on Friday, hitting $29.81. The stock had a trading volume of 323,818 shares. Aegerion Pharmaceuticals has a 52-week low of $26.25 and a 52-week high of $101.00. The stock has a 50-day moving average of $30.52 and a 200-day moving average of $41.81. The company’s market cap is $879.2 million.

Aegerion Pharmaceuticals (NASDAQ:AEGR) last released its earnings data on Tuesday, July 29th. The company reported ($0.33) EPS for the quarter, beating the Thomson Reuters consensus estimate of ($0.41) by $0.08. The company had revenue of $36.00 million for the quarter, compared to the consensus estimate of $35.40 million. During the same quarter in the prior year, the company posted ($0.66) earnings per share. The company’s quarterly revenue was up 453.8% on a year-over-year basis. Analysts expect that Aegerion Pharmaceuticals will post $-0.86 EPS for the current fiscal year.

Aegerion Pharmaceuticals, Inc (NASDAQ:AEGR) is a biopharmaceutical company focused on the development and commercialization of therapeutics to treat lipid disorders.

Receive News & Ratings for Aegerion Pharmaceuticals Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aegerion Pharmaceuticals Inc and related companies with Analyst Ratings Network's FREE daily email newsletter.